Prospects for liquid biopsy using microRNA and extracellular vesicles in breast cancer

Takahiro Ochiya,Kazuki Hashimoto,Akihiko Shimomura

DOI: https://doi.org/10.1007/s12282-024-01563-9

2024-03-31

Breast Cancer

Abstract:Among the analytes circulating in body fluids, microRNAs, a type of non-coding RNA and known to exist 2655 in primates, have attracted attention as a novel biomarker for cancer screening. MicroRNAs are signaling molecules with important gene expression regulatory functions that can simultaneously control many gene functions and multiple different pathways in living organisms. These microRNAs are transported in extracellular vesicles (EVs), which are lipid bilayers with 50–150 nm in diameter, and are used as communication tools between cells. Furthermore, the EVs that carry these microRNAs circulate in the bloodstream and have other important implications for understanding the pathogenesis and diagnosis of breast cancer. The greatest benefit from cancer screening is the reduction in breast cancer mortality rate through early detection. Other benefits include reduced incidence of breast cancer, improved quality of life, prognosis prediction, contribution to personalized medicine, and relative healthcare cost containment. This paper outlines the latest developments in liquid biopsy for breast cancer, especially focusing on microRNA and EV diagnostics.

oncology,obstetrics & gynecology

What problem does this paper attempt to address?

The main problem that this paper attempts to solve is to use microRNA in blood and extracellular vesicles (EVs) through liquid biopsy technology to detect breast cancer early and explore its potential application in breast cancer diagnosis. Specifically, the research focuses on the following points:

1. **Early detection of breast cancer**: As mentioned in the paper, by analyzing specific combinations of microRNA in the blood, early detection of breast cancer can be achieved. The research team has identified several combinations of microRNA with high sensitivity and specificity, which can effectively distinguish healthy individuals from breast cancer patients and even make accurate diagnoses in the early stages of cancer.

2. **Increasing the screening rate**: Since current cancer screening methods have certain limitations, such as the problems of false - negative and false - positive results, and low screening participation, the paper explores how to increase the popularity of cancer screening through a simpler and lower - cost liquid biopsy technology, especially for breast cancer, a common and deadly type of cancer.

3. **Reducing medical costs**: By detecting breast cancer early, treatment costs and patients' pain can be significantly reduced, while the cure rate and quality of life can be improved. The paper discusses how to use liquid biopsy technology to conduct efficient cancer screening in large - scale populations to achieve the above - mentioned goals.

4. **Understanding the biological mechanisms of breast cancer**: In addition to clinical applications, the paper also explores the mechanisms of action of microRNA and EVs in the occurrence and development of breast cancer, including how they affect the tumor microenvironment and promote the metastasis of cancer cells. This helps to deeply understand the pathophysiological process of breast cancer and provides a theoretical basis for the development of new treatment strategies.

In summary, this paper aims to solve the problems existing in current breast cancer screening by exploring and validating the application of liquid biopsy technology in the early diagnosis of breast cancer, improve screening efficiency and accuracy, and ultimately achieve early detection and treatment of breast cancer and improve the prognosis and quality of life of patients.